Sunday, May 26, 2013 Last update: Yesterday, 8:34 AM
Company Tech News as it Breaks
Trade Events
GTx, Inc.
News articles for GTx, Inc.:
Friday, May 3, 2013
- GTx Provides Corporate Update and Reports First Quarter 2013 Financial ResultsGTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the first quarter of 2013. “We expect ... read more
Tuesday, April 30, 2013
- GTx Initiating Phase 2, Open-Label Study of Enobosarm to Treat ER Positive Metastatic Breast CancerGTx, Inc. (Nasdaq: GTXI), announced today that it is initiating a proof of concept, Phase 2, open-label clinical study to evaluate enobosarm (GTx-024), a selective androgen receptor modulator ... read more
Friday, April 19, 2013
- GTx, Inc. To Host First Quarter 2013 Financial Results Conference Call and WebcastGTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's first quarter 2013 financial ... read more
Monday, April 15, 2013
- GTx's Phase III Clinical Studies of Enobosarm (GTx-024) to Continue as Planned Following Planned Safety ReviewGTx, Inc. (Nasdaq: GTXI) today announced that a per protocol safety review of unblinded safety data on Friday April 12, 2013, by an independent Data Safety Monitoring Board ... read more
Tuesday, March 19, 2013
- GTx-758 Poster Presentation of Phase II Trial Data in Advanced Prostate Cancer Selected as One of the Best Posters at the 28th Annual European Association of Urology CongressGTx, Inc. (NASDAQ: GTXI) announced today that its poster presentation entitled, “GTx-758, an ERα agonist, reduces serum free testosterone lower than can be achieved by leuprolide with a ... read more
Thursday, March 14, 2013
- Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function in Patients with Cancer Published in The Lancet OncologyGTx, Inc. (Nasdaq: GTXI) today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition (www.thelancet.com/journals/lanonc/onlinefirst) the results from GTx’s randomized, double-blind, ... read more
Wednesday, February 27, 2013
- GTx Announces Webcast of Corporate Presentation at Cowen and Company 33rd Annual Health Care ConferenceGTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 6, 2013 at the Cowen and Company 33rd Annual Health Care Conference in ... read more
Thursday, February 21, 2013
- GTx Provides Corporate Update and Reports 2012 Financial ResultsGTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the fourth quarter and full year 2012. ... read more
Tuesday, February 19, 2013
- GTx Announces Webcast of Corporate Presentation at 2013 Citi Global Healthcare ConferenceGTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on February 25, 2013 at the 2013 Citi Global Healthcare Conference in New York City. ... read more
Thursday, February 14, 2013
- GTx To Present Preclinical Data on a New Therapeutic Target in Prostate CancerGTx, Inc. (NASDAQ: GTXI) announced today that new preclinical data will be presented indicating that AKR1C3, a steroidogenic enzyme, is an androgen receptor-selective coactivator and promoter of growth ... read more
Wednesday, February 13, 2013
- Novel Findings from Clinical Studies Examining the Effects of Capesaris® (GTx-758) for the Treatment of Advanced Prostate Cancer to be Presented at 2013 American Society of Clinical Oncology GenitouriGTx, Inc. (NASDAQ: GTXI) announced today that new data from two Phase II studies on the effects of Capesaris® (GTx-758), a selective estrogen receptor alpha agonist, for the ... read more
Tuesday, February 12, 2013
- GTx Announces Webcast for Capesaris®(GTx-758) Analyst DayGTx, Inc. (Nasdaq: GTXI) announced today a webcast discussing Capesaris®(GTx-758) and it’s potential role in the treatment of advanced prostate cancer in men is scheduled for Friday, February ... read more
Thursday, February 7, 2013
- GTx, Inc. to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call and WebcastGTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's fourth quarter and full ... read more
Tuesday, February 5, 2013
- GTx Announces Webcast of Corporate Presentation at Bio CEO & Investor ConferenceGTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on February 11, 2013 at the Bio CEO & Investor Conference in New York City. ... read more
Tuesday, January 8, 2013
- GTx Announces FDA’s Grant of Fast Track Designation to Enobosarm For the Prevention and Treatment of Muscle Wasting in patients with Non-Small Cell Lung CancerGTx, Inc. (Nasdaq: GTXI) today announced that the U.S. Food and Drug Administration (FDA) has designated enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients ... read more
Monday, December 17, 2012
- GTx Attains Enrollment Goal for its Enobosarm POWER 1 and POWER 2 Phase III Clinical StudiesGTx, Inc. (Nasdaq: GTXI) today announced that it has attained its enrollment goal for both of its pivotal Phase III clinical studies of enobosarm to prevent and treat ... read more